1. Scrip
  2. >>Business
  3. >>Deals

Collegium, BioDelivery To Combine Pain Portfolios In Proposed Merger

 
• By Joseph Haas

Collegium has offered a 54% share premium to acquire competitor BioDelivery, in an offer approved by both firm’s boards. The $604m price tag would double the size of Collegium’s product portfolio.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.
Collegium and BioDelivery have agreed to a merger joining their pain medication portfolios

In a proposed merger of two pain-focused specialty pharmas, Collegium Pharmaceutical, Inc. will acquire BioDelivery Sciences International, Inc. for approximately $604m, the companies announced on 14 February. On a same-day investor call, Collegium CEO Joseph Ciaffoni said BioDelivery was his firm’s top acquisition target because of complementary product portfolios and the expectation of rapid accretion, as well as an estimated $75m in synergies.

The deal would primarily combine Collegium’s Xtampza ER, an extended-release formulation of oxycodone indicated for chronic lower back pain (CLBP),...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By Kevin Grogan

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

Bristol Myers Shifts Five Drugs To Bain-Partnered Immunology Venture

 
• By Manas Mishra

Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.

Private Equity Targets Bavarian Nordic But Major Investor Balks

 
• By Manas Mishra

After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 
• By Dexter Jie Yan

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

More from Business